

RESEARCH

Hybrid diffuse optical appraisal of peripheral and cerebral changes in critically ill patients receiving red blood cell transfusion

Susanna Tagliabue^{1*}, Anna Rey-Perez², Lourdes Esposito², Andrés F. Jimenez², Sara Valles Angulo², Federica Maruccia^{1,3}, Jonas B. Fischer¹, Michal Kacprzak¹, Maria A. Poca^{2,4,5} and Turgut Durduran^{1,6}

* Correspondence:

Susanna.Tagliabue@icfo.eu

¹ICFO-Institut de Ciències

Fotòniques, The Barcelona

Institute of Science and

Technology, Barcelona, ES

Full list of author information is available at the end of the article

Abstract

Background:

Red blood cells transfusions (RBCT) are utilized to restore normal values of hemoglobin concentration and hematocrit percentage in anemic patients. As expected, RBCT often leads to local and global alteration of blood flow (BF) and blood/tissue oxygenation which could have local deleterious consequences. This complicates its use and its dosage and there is no consensus on liberal versus restrictive RBCT in critically ill patients. Blood gas sampling is utilized to bring objectivity to RBCT which is a reliable systemic measure. However, it is also hypothesized that the knowledge about the dynamic response of selected organs could improve RBCT outcomes. We carried out a study using non-invasive hybrid diffuse optics (DO) to assess the RBCT effect on the brain and a peripheral muscle by evaluating microvascular BF, oxygen extraction fraction (OEF) and microvascular oxy-, deoxy- and total hemoglobin concentrations ([HbO₂], [Hhb], [HbT]) in critically ill patients. We explored the DO's ability to identify RBCT-induced significant alterations and to provide a quantitative description.

Methods: Critically ill anemic patients undergoing RBCT were recruited and monitored by hybrid DO. Blood gas samples were extracted to obtain arterial total hemoglobin concentration (Hgb) and hematocrit value. Optical signals, such as BF, OEF, metabolic rate of oxygen extraction (MRO₂), [HbO₂], [Hhb] and [HbT] were simultaneously measured at the cerebral and the peripheral tissues. The changes in these variables were investigated characterizing the distributions of the cerebral and of the peripheral post-RBCT variables.

Results: Fourteen out of fifteen recruited subjects were included. After RBCT, Hgb and hematocrit significantly increased ($p < 0.001$). OEF significantly decreased both at peripheral and cerebral level ($p < 0.001$, $p < 0.001$). A significant increase was found in MRO₂ ($p = 0.03$, $p < 0.001$), [HbT] ($p = 0.01$, $p < 0.0001$) and [HbO₂] ($p = 0.008$, $p < 0.0001$) at both levels. BF significantly decreased only at the peripheral level ($p < 0.001$). No change was encountered in [Hhb] ($p > 0.05$). No statistical difference was found between cerebral and peripheral signals post-RBCT ($p > 0.05$) apart from MRO₂ ($p = 0.03$, higher at peripheral tissue).

Conclusions: Hybrid DO detected tissue oxygenation improvement after RBCT, enabling a thorough examination. The potential for DO to quantify and alert changes of concern deserves further investigation.

Keywords: hybrid diffuse optics; anemia; red blood cells transfusion; blood flow; metabolic rate of oxygen; oxygen extraction fraction; diffuse correlation spectroscopy; time-resolved spectroscopy; critically ill; intensive care unit

Background

Anemia is a common complication observed in critically ill patients admitted to the intensive care unit (ICU). In the ICU setting, anemia can result from severe bleeding after trauma, acute blood loss or hemorrhage during surgery and in non-bleeding but acutely ill patients experiencing a fast decrease in the hemoglobin concentration in blood [1]. Typically, anemia is defined by low arterial oxy-hemoglobin concentration (HgbO₂) in blood or low hematocrit (HCT) percentage (about 8-10 g/dL [2, 3] and 30% [4] respectively) relative to normal values (about 14-15 g/dL and 35-50% respectively)^[1]. This is quite common for the general ICU critically ill population within the first three days after admission.

In anemic condition, low HgbO₂ translates into reduced oxygen supply, release and diffusion into tissues. This affects the blood flow (BF, cerebral blood flow (CBF) when related to the brain, peripheral blood flow (PBF) when related to peripheral parts of the body) [2], due to its relationship with the oxygen delivery (DO₂), which is the product of BF and arterial oxygen content (CaO₂) [4, 5]. As such, anemia can have deleterious effects on the patient health [2, 5] and extended anemia must be avoided [6] with interventions to restore its normal levels as soon as possible.

As an intervention, patients are generally transfused with units of red blood cells (RBC) [1] and often benefit from this RBC transfusion (RBCT). This intervention is accepted by most clinicians [1, 4], with the objective to restore the content of HgbO₂. For the purposes of this manuscript, among other things, RBCT alters the BF [1, 6] and other physiological parameters directly related to them, such as the arterial total hemoglobin concentration (Hgb), the tissue oxygen saturation (StO₂), the metabolic rate of oxygen (MRO₂) and the oxygen extraction fraction (OEF). In the case of healthy brain, cerebral autoregulation and other protective mechanisms ensure that, at a local level, these changes are not impairing the brain function. For the non-critical organs, such as peripheral muscles, this may not be the case and large, possibly unsustainable changes may be observed. In other words, the balance of local hemodynamics and metabolism can be altered by RBCT.

Nonetheless, the indications for RBCT for critical care patients are subject of considerable debate among clinicians. For example, the “Transfusion Requirements in Critical Care (TRICC)” study, published in 1999 [5, 7] and reviewed in 2012 [8], questioned whether transfusions are appropriate, especially in ICU patients with acute brain injuries, and their risk-benefit ratio [2, 4-6, 9].

Several studies have reported side effects of RBCT in traumatic brain injury (TBI) patients [4] and recent guidelines recommend a more restrictive transfusion strategy for them, with a HgbO₂ threshold of 7g/dL or lower [1-4, 8, 10, 11]. In fact, although in TBI patients anemia is a recognized contributing factor to secondary injury [4, 12] and is associated with increased morbidity, poorer neurological outcome [2, 4, 6] and higher mortality [6], their brain is more vulnerable to the hypoxic damage that may be caused by RBCT [2, 4, 12, 13]. This may be because cerebral autoregulation [2, 4], the systemic cardiovascular response and neuroprotection mechanisms are frequently impaired [2].

Furthermore, TBI patients usually present low CBF [2, 4, 6, 14], which increases the risk of ischemia whenever the oxygen supply cannot meet anymore the demand

^[1]Details about the terminology and acronyms used in this article are reported in the **Appendix**.

[2]. This may be worsened by RBCT if blood is directed from the brain to the peripheral organs in response to the treatment. The identification of the hemodynamic and metabolic evolution that RBCT induces in the brain versus peripheral muscle could indicate to which extent the vulnerable brain of neurocritical patients is affected and with respect to the peripheral system.

For this reason, advanced photonics methods based on non-invasive hybrid diffuse optics (DO) that utilize near-infrared light can be exploited. Hybrid DO, comprising time-resolved spectroscopy (TRS) and diffuse correlation spectroscopy (DCS), could provide more complete overview of the physiological alterations. DCS offers insight about the BF (CBF and PBF), while TRS on the StO_2 , microvascular oxy- and deoxy-hemoglobin concentrations ($[\text{HbO}_2]$ and $[\text{Hhb}]$), total microvascular hemoglobin concentration ($[\text{HbT}]$), OEF (COEF when cerebral, PEOF when peripheral). Together they convey information about the MRO_2 (CMRO_2 when cerebral, PMRO_2 when peripheral). The literature on the effects of RBCT on these signals is quite limited [15]. Continuous-wave near-infrared spectroscopy (NIRS) is the most commonly employed method to measure blood oxygen saturation [5, 15] with few studies on children (i.e. premature babies) [16–22] and fewer in adults [9, 23–26].

We have conducted a pilot study where both local cerebral and peripheral continuous monitoring were performed by hybrid DO throughout RBCT in critically ill patients. This study was exploratory and observational, seeking to inspect cerebral and peripheral hemodynamic and metabolic biomarkers and aiming at demonstrating the capability of DO spectroscopic techniques in quantifying changes due to RBCT.

Study hypotheses

In this study, we aimed at describing and quantifying the response to RBCT for all optically-derived physiological signals. We have hypothesized that RBCT affects them and wanted to verify whether these changes were significant with respect to initial, baseline values prior to the RBCT. We did this both at peripheral and cerebral level, to further inspect whether the response and the amount of their response differed between sites. This allows for the assessment of potential deleterious effects after RBCT.

Material and methods

Subjects and clinical protocol of management

Critically ill patients aged 16-72 admitted to the neurotrauma ICU of the Vall d'Hebron University Hospital (VHUH) between June 2019 and July 2021 that required blood transfusion were included in the study. Despite being created to admit trauma patients, this ICU actually sometimes admits critical patients of different etiologies, such as patients with cerebral hematomas, cerebrovascular damage and large burns, either with a trauma or not, that often lose fluids and blood due to their condition. Among all critically ill patients, we have recruited: 1) polytrauma patients with (abnormal admission computed tomography (CT) scan) or without (normal CT scan) moderate or severe TBI (Glasgow coma scale (GCS) ≤ 13), 2) patients with ischemic or hemorrhagic stroke and 3) patients with severe burns.

Severe TBI patients were treated following the Brain Trauma Foundation (BTF) guidelines [27] and the neuromonitoring protocol included continuous intracranial pressure (ICP) and cerebral oxygenation (PbrO₂) implanted in the most injured hemisphere. The rest of the patients were treated under standard care of critically ill patients and the above TBI guidelines were transposed to them when necessary.

Anemia was defined as a HgbO₂ ≤ 13 g/dL for adult males and ≤ 12 g/dL for adult non-pregnant females. Below these oxy-hemoglobin values, a blood transfusion was indicated. RBC bags were provided for allogenic transfusion by the hospital transfusion services (blood bank), tested for compatibility, verified for blood type and cross-match, that were completed within the prior 96 hours. Whole blood (RBC, platelets, fluids, etc.) was administered after a health care provider request.

Study protocol

A schematic of the measurement protocol and probe positioning is provided in **Figure 1**. One optical probe was placed on the forehead of the recruited subject, while at bedside (cerebral placement). CT scans were checked prior to the measurements whenever available to inspect the tissue and decide the optimal positioning. Accordingly, the hemisphere more easily accessible and/or without underlying trauma was always preferred for the probe placement. A second probe was preferably placed on the *quadriceps femoris* or, if not accessible, on the *brachioradialis* muscle (peripheral placement).

After the positioning of the optical probes, critical care personnel re-verified the blood bag compatibility with the patient and the standard transfusion procedure was followed.

The continuous monitoring of the patients was carried out before, during, and after transfusion with a protocol of 30 minutes of baseline (pre-RBCT), 2-3 hours-long RBCT and 30 minutes of observational post-transfusion monitoring (post-RBCT). The timing of each period was adjusted according to the situation as illustrated in **Figure 1**.

Standard vials of blood samples were also extracted from an artery (generally the *arteria radialis*) through a catheter during the protocol at baseline, when the half the blood bag was transfused and during the observational final period, for a total of three times. In the ideal scenario, the initial and final blood samples were taken about 10 minutes after each protocol part begun, but was adjusted according to the decisions of the medical personnel.

In order to standardize the protocol and its duration, we have decided to carry out our study only after one single RBCT even in those cases where more blood bags were indicated to restore the patient hemoglobin values.

Clinical monitoring

Standard bedside monitors were used to collect physiological and clinical parameters. Mean arterial blood pressure and heart rate were measured by available sensors and were recorded by the critical care monitor (IntelliVue MX800 or MX750, Koninklijke Philips N.V., Netherlands). Peripheral arterial oxygen saturation was measured by a standard pulse-oximeter (Nellcor DS100A-1, Medtronic, United States of America) through a capnograph with a pulse-oximeter unit (CapnostreamTM 20p, Medtronic, United States of America).

A dedicated software (LabChart, version 6 and 8.1, ADInstruments Ltd, United Kingdom) and hardware (PowerLab, ADInstruments Ltd, United Kingdom) recorded all digitized vital signals at a sampling frequency of 400 Hz alongside a synchronization signal from the hybrid DO device.

The samples of arterial blood were analyzed by a co-oximeter (GEM Premier 4000, Werfen, Spain) to obtain the levels of arterial carbon-dioxide (PaCO_2), HgbO_2 , arterial reduced hemoglobin concentration (HgbR), arterial total hemoglobin concentration (Hgb) and HCT.

Patient demographic information was also collected, including sex, age and etiology.

Optical monitoring

A hybrid DO device, previously described in References [28, 29] and similar to Reference [30], comprising of diffuse correlation spectroscopy (DCS) and time-resolved spectroscopy (TRS), was used for the non-invasive optical measurements. Both techniques are based on diffuse near-infrared spectroscopy methods [31]. DCS quantifies the motion of scatterers inside of the probed tissue volume which measures BF [32]. TRS recovers the wavelength dependent absorption and scattering of the probe tissue volume [31, 33]. In human tissues, these quantities allow one to retrieve $[\text{HbO}_2]$, $[\text{Hhb}]$, $[\text{HbT}]$ and StO_2 [31, 33]. Further details about the optical device, probe adhesion and data acquisition can be found in Reference [28]. Real-time movement monitoring was employed using accelerometers on programmable boards placed at the two distinct patient placements, above the probes.

Events were marked within the software routine and data were synchronized with high precision with the ones provided by the clinical monitors as described above.

Data evaluation

DO analysis for the collected data followed the standard procedures for fitting methods for both TRS and DCS techniques [33–35] and making use of Matlab (Release 2018b, The MathWorks, Inc. Natick, Unites States of America). The optically-derived parameters of interest in this study were: $[\text{HbO}_2]$, $[\text{Hhb}]$, $[\text{HbT}]$, BF, OEF, MRO_2 . Again, each acronym is preceded by a ‘C’ when referred to the cerebral tissue and by a ‘P’ when peripheral tissue. Probe placement was described above and shown in **Figure 1**.

Strict rejection criteria were applied to the data according to the signal-to-noise ratio (SNR) and the measurement session quality as detailed in Reference [28]. Additionally, accelerometers information was inspected when an artifact was suspected from the marks. In this work, the SNR for TRS was defined as the ratio between the maximum of the TRS distribution of time-of-flight, which is the retrieved curve built by the photons distribution after the initial laser pulse traverses the tissue, and the standard deviation of a background portion of the same signal prior to the curve. The threshold value was $\text{SNR} > 10$. DCS measurements were rejected if the averaged count-rate of the detector channels to build the autocorrelation function was lower than 10 kHz and β parameter was lower than 0.4 [34].

The non-rejected time-traces of the mentioned variables were then synchronized with the clinical signals by exploiting the common time-base signal. Further parameters, like OEF and MRO_2 , based on both optical and clinical data, were derived as described in References [28, 34, 35].

Since recent studies showed the need to apply corrections to DO signals calculations when HCT changes significantly during measurements [36, 37], a correction in the MRO_2 time-traces calculation was implemented. Accordingly, MRO_2 calculation was also corrected by the HCT value measured by the blood gas analysis and similarly to Reference [38]. To do so, in the following expression:

$$MRO_2 = BFI \times OEF \times CaO_2 \quad (1)$$

the arterial oxygen content (CaO_2) was computed as

$$CaO_2 = k \times Hgb \times SaO_2 \quad (2)$$

where k was assumed equal to 1.36 mL O_2 /1gHgb for mammals and the arterial total hemoglobin concentration was expressed as

$$Hgb = \frac{HCT[\%]}{100} \times \frac{MCHC}{10}. \quad (3)$$

In the latter equation, MCHC is the mean corpuscular hemoglobin concentration and was assumed to be the averaged value 340 g/L. For SaO_2 , the time-trace collected by the additional monitors was used. Since in this study HCT was available in three moments only, the computation of MRO_2 was done separately for each period of the protocol with its respective HCT value kept as a constant.

All the optically derived hemodynamic signals were calculated for cerebral and peripheral areas below the probe placements separately. PBF, POEF, $PMRO_2$ and their cerebral counterpart time-traces were referred to their pre-RBCT baseline period by dividing the entire time-trace by the pre-RBCT mean value. The baseline pre-RBCT lasted from the beginning of the recording to the beginning of the RBCT, marked as “transfusion start”. In this case, an “r” was added to describe these variables as relative (i.e. relative CBF = rCBF). Instead, [HbT], [Hb O_2] and [Hhb] were calculated as difference changes and, therefore, each time-trace was subtracted by its average over the baseline pre-RBCT period. This led to Δ [HbT], Δ [Hhb] and Δ [Hb O_2] for both peripheral and cerebral probes.

The data related to vital signals collected by external available monitors were read in software during post-processing and synchronized with the optical time-traces. All data were down-sampled to 10 second bins.

Marked events were reported on all physiological time-traces. This led to further artifact identification and removal corresponding to periods of patient manipulation due to clinical procedures. Similarly, the visual inspection of data allowed the identification of features such as movement artifacts.

Relevant blood-derived parameters obtained by the output of the blood gas analyzer were collected for each subject in a database together with all demographic and clinical patient information.

Statistical analysis

All statistical analyses were carried out with R (v4.0.1, R Core Team, USA) and the integrated development environment RStudio (v1.1.5042, RStudio, Inc., USA). In particular, the *nlme* v. 3.1-152, *lme4* v. 1.1-27, *lmerTest* v. 3.1-3 and *stats* v. 3.6.3 packages were utilized.

Descriptive statistics was computed for each variable. Clinical variables and demographic information (i.e. sex) were summarized as mean(standard deviation (SD)) or proportions (i.e. males:females as M:F).

Variables obtained at specific time-points by blood gas samples (up to three times per measurement session), i.e. Hgb, HCT and PaCO₂, were summarized by mean(SD) both before (pre-) and after (post-) transfusion. Pre-transfusion values were compared to post-transfusion ones by Wilcoxon paired tests.

Continuous normally distributed optically-derived hemodynamic time-traces underwent a windowing procedure in order to define pre- and post-transfusion values, both at the cerebral and peripheral levels. The pre-transfusion window was selected lasting the entire pre-RBCT period, prior to marking the beginning of the RBCT. The post-transfusion window included the six minutes after the marked event of RBCT end. The values within the windows were averaged and collected separately into two distributions, one for the cerebral and one for the peripheral placement.

For each variable, the difference between the post-transfusion distribution of mean values with respect to its pre-RBCT distribution was tested by unpaired Wilcoxon test: the mean of the pre-RBCT was subtracted to the post-RBCT distribution (providing a relative mean) and its difference from zero tested. For the distributions of variables which were expected to be increased after transfusion, one-sided Wilcoxon tests were used to check whether the relative change was greater than zero (with “greater” option for the test applied), while one-sided test to check whether the relative mean was less than zero (with “less” option employed) for those variables expected to show a decrease. Significance was attributed when p-values (p) were lower than 0.05 and all values lower than 0.001 were reported only as p<0.001.

Furthermore, the paired Wilcoxon test was used to compare cerebral and peripheral pre-transfusion distributions of values to make sure that there were no initial differences (thus discarding cases where one placement was not available, i.e. cerebral missing but peripheral available). Paired Wilcoxon tests were also used to test the difference between cerebral and peripheral data distributions post-transfusion.

Boxplots (median, first and third interquartile ranges (IQR)) for all pre- and post-RBCT distributions of mean values and variables, separated between cerebral and peripheral placements, were depicted to visualize the data. The median values with respect to the baseline pre-RBCT were used to identify the direction of the change for the distribution, for instance an increase if it was greater than the baseline and statistically significant.

Results

Population characteristics

Fifteen subjects were recruited (see **Table 1**) with ten patients with polytrauma, three with ischemic or hemorrhagic stroke and two with severe burns. The data from one subject had to be discarded due to poor SNR in the optical measurement

(according to the criteria described above) both on the head (effect of the trauma) and the peripheral muscle (scar tissue due to an old burnt). Furthermore, two data sets from the probe in the cerebral placement were discarded due to poor SNR.

Consequently, fourteen subjects were included in the following analysis out of which all the measurement sessions had peripheral measurements of the optical variables (time-traces), while twelve also had cerebral hemodynamic time-traces. Moreover, in one subject the peripheral measurement had to be carried out on the *brachioradialis* muscle due to inaccessibility of the *quadriceps femoris* muscle.

In one subject, the vial of blood sample was extracted only prior to the measurement due to the care provider decision. In this case, for the hematocrit correction of MRO_2 , it was decided to use as post-transfusion value the average over all of the other subjects' post-transfusion HCT values which had started from the same initial HCT value as this subject.

The mean age of the fourteen included patients was 39(19) years (median: 35, minimum: 16, maximum: 72 years) and the proportion of males to females was 11:3. **Table 1** summarizes the demographic and clinical data of the patients. Descriptors for the variables related to the blood gas samples are summarized in **Table 2**. For the included subjects, the average RBC bag volume was 306(22) mL and the average bag age was 21(5) days.

Representative data during transfusion

A representative set of data (male, age range 18-23 y.o., with polytrauma and severe TBI) is presented in **Figure 2** (case 2 in **Table 1**) where darker curves show data from the peripheral muscle ($rPBF$, $rPOEF$, $rPMRO_2$) and the lighter curves correspond to data from the brain ($rCBF$, $rCOEF$, $rCMRO_2$). The start and the end of the RBCT are indicated by vertical dashed lines. Additional events, such as blood gas sampling and movements, are depicted by lighter vertical lines. Initial Hgb, HCT and PaCO_2 values were 7.9 g/dL, 26 % and 36 mmHg respectively.

By eye, it can be seen that there is a general trend for the $rCBF$ to decrease with respect to the pre-RBCT period, while the $rPBF$ has an increasing trend. Instead, $rOEF$ shows a decreasing trend for both peripheral and cerebral signals. The response of the metabolic rate of oxygen extraction is more subtle with a small decrease in $rCMRO_2$ by the end of the protocol.

Pre- and post-transfusion comparisons

As far as blood gas samples-related variables are concerned, the results of the comparison between pre-RBCT and post-RBCT distributions of mean values to check whether a significant change occurred are provided in **Table 2**, where the p-values and direction of changes are reported. RBCT caused a significant increase in the Hgb by about 0.9 g/dL ($p < 0.001$) and HCT measured by blood gas samples by about 3% ($p < 0.001$). PaCO_2 did not show any significant change ($p = 0.22$).

In relation to the tests for pre- and post-transfusion distributions from the hemodynamic time-traces, the results are detailed in **Table 3** and depicted in **Figure 3**. Differences between cerebral baseline pre-RBCT distributions and peripheral baseline pre-RBCT distributions for all variables were not statistically significant ($p > 0.05$) and were omitted from the **Table**. All post-transfusion test results are

provided together with the direction (Dir.) of the change with respect to the baseline. Moreover, the results of the tests between the post-RBCT cerebral values and the peripheral values are reported in the third column.

RBCT provoked a significant increase ($p < 0.001$) in rPBF by 68% (by comparing the percent change between the median post- to median pre-values), while no significant change in rCBF was observed ($p = 0.07$). rPOEF median value fell significantly by 8% ($p < 0.001$) and rCOEF by 7% ($p < 0.001$) with respect to their pre-RBCT values. The median rPMRO₂ significantly raised by 89% ($p < 0.001$) and rCMRO₂ by 10% ($p = 0.03$), with a significantly greater median increase in the muscle by 79% than in the brain ($p = 0.03$). No significant differences were found in the post-RBCT comparison for the other hemodynamic signals ($p = 0.1$ for rBF, $p = 0.2$ for rOEF).

Both $\Delta[\text{HbO}_2]$ and $\Delta[\text{HbT}]$ had a significant increase both at cerebral and peripheral levels, with similar median shift with respect to baseline pre-RBCT values (as visible in **Figure 3**). $\Delta[\text{HbO}_2]$ increased by 0.0040(0.0053) mMol on the brain and 0.0036(0.0014) mMol on the muscle; $\Delta[\text{HbT}]$ raised by 0.0041(0.0071) mMol on the brain and 0.0034(0.0016) mMol on the muscle. Instead, $\Delta[\text{Hhb}]$ had no significant changes ($p = 0.2$ and $p = 0.1$ for cerebral and peripheral placements, respectively). No statistical difference was found between post-RBCT cerebral versus peripheral placement for any of these variables.

Discussion

The study aimed at demonstrating the usefulness of hybrid DO to quantify the physiological changes after RBCT and in providing a preliminary characterization of the response at both the peripheral muscle and the brain in a small, pilot population of critically ill patients. We have obtained a rich array of signals. Since the RBCT response for the invasive and standard variables is well-documented, we focus on discussing the results of the optical monitoring with respect to the literature.

RBCT provoked a significant increase in rPBF, while no significant change in rCBF was observed. However, this is in contrast with the results obtained on the brain in ill but young populations (i.e. sickle cell disease, very preterm infants) where a decrease in the CBF was found after the intake of blood [15, 20, 39]. For instance, in Reference [20], the decrease of cerebral blood volume (CBV) was 0.5 mL/100g, while in Reference [39] CBV decreased by median 18.2% and CBF by median 21.2%. However, we acknowledge that the populations, the age, the origin of their anemia and the etiology are not fully relatable and may account for these discrepancies. As for alternative monitoring methods, for example, a reduction by 18% in the blood flow velocity measured by transcranial Doppler ultrasound (TCD) was found in stroke patients after 3h post-RBCT both on infarcted and non-infarcted regions, with significantly lower baseline values for the infarcted areas [40]. Nonetheless, in another study involving subarachnoid hemorrhage (SAH) patients monitored by ¹⁵O-positron emission tomography (PET), post-RBCT global CBF values remained unchanged [41], similar to our findings. Differences in the post-RBCT CBF response between children and adults with sickle cell anemia were also found by magnetic resonance imaging (MRI) and magnetic resonance angiography [42]: post-RBCT CBF did not significantly change in the adults (N=16), while it significantly decreased in the children (N=10, with -22.3 ml/100g/min in 9/10 participants). In Reference

[43], CBF evaluated in children with sickle cell anemia by MRI with arterial spin labeling significantly decreased by 6.5 mL/100g. These findings are mostly in contrast with our results. However, a possible explanation may lie again in the etiology itself and the age of the participants. Moreover, the differences may be due to the fact that we have decided to monitor only the transfusion of a single RBC bag, the first one, even when more units had been assigned to the patient. This was done in order to be consistent among patients and be able to compare the amount of change of the physiological signals. According to literature, greater changes are expected when more bags are transfused [44].

Concerning TRS-related results for oxygenation and hemoglobin, we will try to discuss them altogether. Moreover, since several NIRS studies characterized the tissue oxygen saturation (StO₂) rather than OEF, but which is generally inversely related to the OEF, we will use it as well as an inverse comparison to our findings. In our study, at cerebral level we encountered a significant decrease in rCOEF, a significant increase in $\Delta[\text{HbO}_2]$ and $\Delta[\text{HbT}]$, no change in $\Delta[\text{Hhb}]$. For rCOEF, this is in agreement with literature and was mainly confirmed in young populations after RBCT [5, 15, 19, 45], although not always a significant change was found [26]. rCOEF significant decrease by 0.06% by CW-NIRS was reported, for instance. Studies using other modalities reported a significant decrease in post-RBCT rCOEF, which was observed both in children and adults with sickle cell anemia evaluated by MRI (-0.1)[42], in children with sickle cell anemia assessed by asymmetric spin echo sequence MRI technique (-2% for the whole brain) [43] and in SAH patients by PET (-0.11)[41]. These results are consistent with ours. Our results are also strengthened by several studies highlighting a significant increase in cerebral StO₂ [17–21, 25, 46–48]. In Reference [17], cerebral regional StO₂ measured by CW-NIRS increased by 17% in infants and by 4.2% in patients undergoing transfusion during aortic or spinal surgery [46]. Only in Reference [26], McCredie *et al.* did not detect any significant change in cerebral StO₂ by bifrontal NIRS measurements in TBI after RBCT. Only one study used a TRS device in infants [20] and found the same: cerebral StO₂ increased by about 2% after transfusion. As for $\Delta[\text{HbO}_2]$ and $\Delta[\text{HbT}]$, our findings are in line with other studies using NIRS [16, 20, 26, 47]. For instance, in Reference [16], $\Delta[\text{HbO}_2]$ was 0.026 mMol and $\Delta[\text{HbT}]$ was 0.02 mMol, and were in the same direction as our study, although with greater absolute value and measured by a frequency domain tissue oximeter.

In our study, at the peripheral level, we have found a significant decrease in rPOEF, a significant increase in $\Delta[\text{HbO}_2]$ and $\Delta[\text{HbT}]$ but no significant change in $\Delta[\text{Hhb}]$. rPOEF result is in agreement with literature [5, 15, 19, 45], where a 0.13% significant decrease in the abdomen was found, for example, comparable to ours. Conversely, a lot of studies highlighted a significant increase in StO₂ peripheral level [17–21, 25, 46–48], which is also in accordance with our study. For instance, peripheral StO₂ increased by 17% in infants [17] and by 1.6% in patients undergoing transfusion during aortic or spinal surgery [46]. The peripheral increase in $\Delta[\text{HbO}_2]$ and $\Delta[\text{HbT}]$ was confirmed by NIRS literature [16, 20, 26, 47]. Regarding $\Delta[\text{Hhb}]$, similarly was found interscapularly by CW-NIRS [16]. However, $\Delta[\text{Hhb}]$ was often reported to decrease in literature.

It is possible to speculate that the variations in [Hhb] were too small and could have probably been more relevant in case of full restoration to normal hemoglobin

concentration and hematocrit values, which were not reached by the end of the measurements due to our protocol choice. Furthermore, some studies highlighted RBCT failure in raising the oxygen uptake except that there is dependency between O_2 uptake and DO_2 , which is generally true only in severe anemic conditions. Generally, more pronounced changes in the brain were found for groups with lower hemoglobin (< 9.7 g/dL) [5, 45].

Both $rPMRO_2$ and $rCMRO_2$ raised due to RBCT, with a greater median increase in the muscle than in the brain and with a statistically significant difference between the two. This result is in disagreement with what was found in some literature related to infants where, for instance, a decrease [15] or no change ($p > 0.05$) [39, 49] had been found in $CMRO_2$ by optical methods. Likewise, no $rCMRO_2$ change was found in SAH patients by PET [41] nor in children with sickle cell anemia by MRI [43]. Further research is needed to clarify these discrepancies.

As for the difference between cerebral and peripheral level response after RBCT, significant statistical difference was confirmed only for $rMRO_2$ tests.

Overall, the findings for the cohort highlight an improvement in oxy- and total hemoglobin concentration and the oxygen supply, both by optical and standard methods, as expected after RBCT. Moreover, with the obtained information, it is possible to evaluate on an individual basis whether these changes pose any risks or lack them. Indeed, while anemia and RBCT are crucial for a patient's recovery, collateral issues may arise, especially in cases of impaired cerebral autoregulation, potentially leading to stemming misery perfusion with consequent risk of cerebral ischemia. In light of the post-RBCT findings for the cohort, for instance, we did not identify any misery perfusion, as defined in Reference [28] nor a hyperperfusion or a hypoperfusion, since the $rCBF$ did not significantly change and the $rCOEF$ significantly decreased.

Cerebral autoregulation is often impaired in critically ill subjects [50, 51], especially in TBI [52]. In such eventuality, systemic changes may directly affect the brain and damage it [52, 53]. Therefore, it is reasonable to assume that if a robust monitor of cerebral autoregulation becomes available, it would be recommendable to utilize it frequently. In our study, the significant decrease in $rCOEF$ along with no change in the $rCBF$ and $rCMRO_2$ suggests that the cerebral autoregulation was at play. In fact, the decrease in the $rCOEF$ indicates that the brain was extracting less oxygen from the blood, potentially allowing for better DO_2 to meet the metabolic demand. This is further supported by the lack of change in $rCBF$ and $rCMRO_2$, indicating a regulation mechanism to maintain consistent oxygen supply. Conversely, the significant $rPBF$ and $rPMRO_2$ increase in quadriceps along with decreased $rPOEF$ indicate hyperemia or luxury perfusion at peripheral level. This suggests an increased supply of oxygen to the quadriceps muscle, possibly to meet increased metabolic demands, that does not imply deleterious consequences. These are rather adaptive responses to ensure adequate oxygen supply and brain protection.

The first strong limitation of this study is the small sample size. This study was a good starting point to prove the feasibility of this method and spares the need for larger clinical trials.

Once more, we recognize that our study protocol design based only on the monitoring during the first RBC bag transfusion may have been a limitation in the sense

of the lower response associated to it than multiple bags. In fact, greater blood exchange may have led to potentially greater changes in our variables and could be worth further exploration to verify whether the results keep consistent over several bags or lead to significant changes.

Another important limitation is the fact that, as mentioned in the “Data evaluation” Section, the correction for the hematocrit value was taken into account in the calculation of the MRO_2 in the analysis. However, in Reference [37] a correction method was outlined for the BFI in phantom experiments. This approach is currently under validation against MRI measurements [39] by the same group and, if confirmed *in vivo*, it would be a further step to implement in the future. Therefore, our calculations of the BFI should be considered as preliminary.

Finally, it is essential to acknowledge the potential influence of the well-known partial volume effect in our study, which is a recognized limitation when using techniques such as DCS and TRS [54, 55]. In fact, they are susceptible to variations in tissue composition within the measurement volume and the presence of different morphological tissue types and structures can lead to uncertainties in the interpretation of the acquired data, for instance the underestimation of rCBF and rOEF. While we made efforts to minimize this effect by carefully selecting measurement locations, the inherent challenge of disentangling signals from multiple tissue types, especially the extracerebral layer, was not entirely eliminated. More advanced analysis could be employed to do so. In our case, the probed tissue composition below the probes also additionally considerably varied between cerebral and peripheral measurement locations.

Conclusion

This work focused on the compatibility of DO measurements and critically ill subjects, whose response to RBCT are more unpredictable with respect to other populations, and quantified it both at cerebral and peripheral levels. However, the applicability could be extended to other populations where anemia is a trigger to RBCT, such as during some types of surgery.

We have shown the potential usefulness of hybrid DO in RBCT management, ideally aiming at improving the RBCT decision-making in the future and paving the way to a widespread implication of hybrid DO monitors in clinical trials about RBCT. The acquired knowledge in this important clinical field could even help in personalizing RBC therapy in critical patients and enhance the quality of transfusion therapies and strategies, avoiding deleterious consequences such as hypoxia, hypoperfusion, hyperperfusion, ischemia and transfusion-associated circulatory overload.

Appendix: terminology

In this Section we clarify the distinction between the parameters derived by blood gas sample analysis from the ones by DO measurements. In fact, these two methods/fields often use the same terminology to define similar parameters although of another origin.

The oxy-hemoglobin concentration that is calculated from a blood gas sample by a co-oximeter refers to the fraction of the amount of hemoglobin present in the

arterial blood that is bound to the oxygen: it corresponds to the level of oxygenated hemoglobin in blood, defining its capability to carry oxygen. In this article, we have used the acronym HgbO_2 and Hgb for the derived oxy- and reduced hemoglobin concentrations. As for the arterial total hemoglobin concentration, it includes the cumulative concentration of various forms of hemoglobin, such as carboxyhemoglobin and methemoglobin, in addition to the previously mentioned ones. We used Hgb to refer to it.

Oxy- and deoxy-hemoglobin concentrations that are derived from TRS measurements provide a non-invasive estimate of the content of such chromophores from deep tissue microvasculature, locally related to a specific tissue region and the underneath volume. This method does not derive these components from the blood only, rather from an average between all tissues regionally interacting with the light source and within its penetration depth. Among the usual acronyms used for optical hemoglobin concentrations, in this article we have decided to adopt the following ones in order to avoid confusion: microvascular deoxy-hemoglobin concentration ($[\text{Hhb}]$) and microvascular oxy-hemoglobin concentration ($[\text{HbO}_2]$). The total microvascular hemoglobin concentration is calculated from the sum of these two latter and acronymized as $[\text{HbT}]$.

We have summarized this in **Table 4**.

Acknowledgements

We take this opportunity to thank the students who helped in setting up the project, Julia Scheel, Marta Grau and Lavinia Herea. We also thank Dr. J. Sahuquillo for his initial role in organizing the project. In addition, we thank all the nurses of the intensive care unit of the Vall d'Hebron hospital for allowing us to carry out the measurements in the best possible conditions, helping us with the handling of patients, extraction of blood samples and administration of transfusions. Finally, we acknowledge the useful discussions with Erin Buckley and Rowan Brothers about the hematocrit correction.

Funding

This work received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 675332 (BitMap), No. 101016087 (VASCOVID) and No. 101017113 (TinyBRAINS). Moreover, the funding was provided by: Fundació CELLEX Barcelona, Fundació Mir-Puig, Agència Estatal de Investigació (PHOTOMETAB, PID2019-106481RB-C31/10.13039/501100011033), the "Severo Ochoa" Programme for Centres of Excellence in R&D (CEX2019-000910-S); LUX4MED and MEDLUX special programs; Generalitat de Catalunya (CERCA, AGAUR-2017-SGR-1380, RIS3CAT-001-P-001682 CECH, and AGAUR-2021SGR/00810), FEDER EC and LASERLAB-EUROPE V (EC H2020 no. 871124), KidsBrainIT (ERA-NET NEURON), la Fundació La Marató de TV3 (201724.31, 201709.31 and 202109-30), "PLEC2022-009290, SafeICP" project funded by MCIN/AEI/ 10.13039/501100011033 and by the "European Union NextGenerationEU/PRTR".

Abbreviations

ICU: Intensive care unit; TBI: Traumatic brain injury; RBC: Red blood cells; RBCT: Red blood cells transfusion; COVID-19: Coronavirus disease 2019; HgbO_2 : Arterial oxy-hemoglobin concentration; Hgb : Arterial reduced hemoglobin concentration; HCT: Hematocrit; TRICC: Transfusion Requirements in critical care; DO_2 : Oxygen delivery; BF: blood flow; CBF: Cerebral blood flow; PBF: Peripheral blood flow; CaO_2 : Arterial oxygen content; StO_2 : Tissue oxygen saturation; TCD: Transcranial Doppler ultrasound; OEF: Oxygen extraction fraction; COEF: Cerebral oxygen extraction fraction; POEF: Peripheral oxygen extraction fraction; $[\text{HbT}]$: Microvascular total hemoglobin concentration; $[\text{Hhb}]$: Microvascular deoxy-hemoglobin concentration; $[\text{HbO}_2]$: Microvascular oxy-hemoglobin concentration; MRO_2 : Metabolic rate of oxygen; CMRO_2 : Cerebral metabolic rate of oxygen; PMRO_2 : Peripheral metabolic rate of oxygen; HR: heart rate; SpO_2 : Oxygen saturation; MABP: Mean arterial blood pressure; CT: Computer tomography; GCS: Glasgow coma scale; BTF: Brain trauma foundation; Hgb : Arterial total hemoglobin concentration; MCHC: Mean corpuscular hemoglobin concentration; SaO_2 : Arterial oxygen saturation; rCBF: Relative cerebral blood flow; rBF: Relative blood flow; rPBF: Relative peripheral blood flow; $\Delta[\text{HbT}]$: Change in $[\text{HbT}]$; $\Delta[\text{HbO}_2]$: Change in $[\text{HbO}_2]$; $\Delta[\text{Hhb}]$: Change in $[\text{Hhb}]$; PaCO_2 : Arterial pressure of carbon dioxide; PbrO_2 : Partial pressure of tissue oxygenation; SD: Standard deviation; p: p-value; SNR: Signal-to-noise ratio; IQR: Interquartile range; ICP: Intracranial pressure; NIRS: Near-infrared spectroscopy; TRS: Time-resolved spectroscopy; DCS: Diffuse correlation spectroscopy; DO: Diffuse optics rOEF: Relative oxygen extraction fraction; rCOEF: Relative cerebral oxygen extraction fraction; rPOEF: Relative peripheral oxygen extraction fraction; r MRO_2 : Relative metabolic rate of oxygen; r CMRO_2 : Relative cerebral metabolic rate of oxygen; r PMRO_2 : Relative peripheral metabolic rate of oxygen; PaO_2 : Partial pressure of oxygen; SaO_2 : Arterial oxygen saturation; MRI: magnetic resonance imaging; PET: positron emission tomography; SAH: subarachnoid hemorrhage; CBV: cerebral blood volume; NA: not available.

Availability of data and materials

Data will be made available by the corresponding author upon reasonable request taking into account the appropriate norms for personal data privacy.

Ethics approval and consent to participate

The study obtained clearance by the ethical committee of Vall D'Hebron University Hospital (PR(AG)160/2017) and was conducted following the Declaration of Helsinki [56]. Signed informed consent was obtained before the measurements either by the patient or a legal representative.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

S.T. had full access to all data in the study and took responsibility for the integrity of the data and the accuracy of the analysis. S.T. performed all optical measurements, data analysis and wrote the manuscript. S.T., M.K. and J.B.F. built the optical device used for the acquisitions. L.E. helped during the data acquisition. A.R., A.F.J. and S.V.A. were responsible of the patient recruitment. F.M. provided clinical information about the patients. M.A.P. and T.D. were responsible of the study design, contributed to the results interpretation and writing of the manuscript. All authors read and approved the final manuscript.

Author details

¹ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Barcelona, ES.

²Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research Institute (VHIR), Barcelona, Spain. ³Neurotrauma Intensive Care Unit, Vall d'Hebron University Hospital, Barcelona, Spain.

⁴Department of Neurosurgery, Vall d'Hebron University Hospital, Barcelona, Spain. ⁵Universitat Autònoma de Barcelona, Barcelona, Spain. ⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.


References

1. Markham C, Hovmand P, Doctor A. Transfusion decision making in pediatric critical illness. *Pediatr Clinics*. 2001;64(5):991 – 1015.
2. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. *Crit Care*. 2009;13:R89.
3. Birlie Chekol W, Teshome M, Addisu Nigatu Y, Yaregal Melesse D. Hemoglobin threshold and clinical predictors for perioperative blood transfusion in elective surgery: Systemic review. *Trends Anaesth Crit Care*. 2020;31:8–15.
4. East JM, Viau-Lapointe J, McCredie VA. Transfusion practices in traumatic brain injury. *Curr Opin Anaesthesiol*. 2018;31(2):219–226.
5. Roberson RS, Bennett-Guerrero E. Impact of red blood cell transfusion on global and regional measures of oxygenation. *Mt Sinai J Med*. 2012;79(1):66–74.
6. Leal-Noval SR, Cayuela A, Arellano-Orden V, Marín-Caballos A, Padilla V, Ferrándiz-Millón C, et al. Invasive and noninvasive assessment of cerebral oxygenation in patients with severe traumatic brain injury. *Intensive Care Med*. 2010;p. 1309–1317.
7. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. *NEJM*. 1999;340(6):409–417.
8. Retter A, Wyncoll D, Pearse R, Carson D, McKechnie S, Stanworth S, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients by the British Committee for Standards in Haematology. *Br J Haematol*. 2013;160(4):445–464.
9. Leal-Noval SR, Arellano-Orden V, Muñoz-Gómez M, Cayuela A, Marín-Caballos A, Rincón-Ferrari MD, et al. Red Blood Cell Transfusion Guided by Near Infrared Spectroscopy in Neurocritically Ill Patients with Moderate or Severe Anemia: A Randomized, Controlled Trial. *J Neurotrauma*. 2017;34(17):2553–2559.
10. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical Practice Guidelines From the AABB: red blood cell transfusion thresholds and storage. *JAMA*. 2016;316(19):2025–2035.
11. Krishna HM, Prasad MK, Mitragotri MV, Bipin GI, Gupta D, Sharma R. Recent advances in perioperative blood management. *Indian J Anaesth*. 2023;67(1):130–138.
12. Utter G, Shahlaie K, Zwienenberg-Lee M, Muizelaar J. Anemia in the Setting of Traumatic Brain Injury: The Arguments For and Against Liberal Transfusion. *Journal of neurotrauma*. 2010 10;28:155–65.
13. Litofsky N, Martin S, Diaz J, Ge B, Petroski G, Miller D, et al. The negative impact of anemia on outcome from traumatic brain injury. *World Neurosurg*. 2016 02;90.
14. Martin NA, Patwardhan RV, Alexander MJ, Zane Africk C, Lee JH, Shalmon E, et al. Characterization of cerebral hemodynamic phases following severe head trauma: hypoperfusion, hyperemia, and vasospasm. *J Neurosurg*. 1997;87(1):9 – 19.
15. Lee SY, Sathialingam E, Cowdrick KR, Brown RC, Joiner CH, Buckley EM. Effect of blood transfusion on cerebral hemodynamics measured by diffuse optical spectroscopies. vol. 11629. *International Society for Optics and Photonics*. SPIE; 2021. .
16. Cerussi AE, Van Woerkom R, Waffarn F, Tromberg BJ. Noninvasive monitoring of red blood cell transfusion in very low birthweight infants using diffuse optical spectroscopy. *J Biomed Opt*. 2005;10(5):1 – 9.
17. Seidel D, Blaser A, Gebauer C, Pulzer F, Thome U, Knupfer M. Changes in regional tissue oxygenation saturation and desaturations after red blood cell transfusion in preterm infants. *J Perinatol*. 2013;33(4):282–287.
18. Schenkman KA, Hawkins DS, Ciesielski WA, Delaney M, Arakaki LSL. Non-invasive assessment of muscle oxygenation may aid in optimising transfusion threshold decisions in ambulatory paediatric patients. *Transfus Med*. 2017;27(1):25–29.

19. Sandal G, Oguz SS, Erdevi O, Akar M, Uras N, Dilmen U. Assessment of red blood cell transfusion and transfusion duration on cerebral and mesenteric oxygenation using near-infrared spectroscopy in preterm infants with symptomatic anemia. *Transfus.* 2014;54(4):1100–1105.
20. Koyano K, Kusaka T, Nakamura S, Nakamura M, Konishi Y, Miki T, et al. The effect of blood transfusion on cerebral hemodynamics in preterm infants. *Transfus.* 2013;53(7):1459–1467.
21. Li L, Wu R, Kong X, Huang L, Wang Z, Hao J, et al. Effect of anemia and blood transfusion on tissue oxygen saturation and blood pressure in very preterm infants. *Int J Clin Exp Med.* 2017;10(2):2974–2979.
22. Whitehead HV, Vesoulis ZA, Maheshwari A, Rao R, Mathur AM. Anemia of prematurity and cerebral near-infrared spectroscopy: should transfusion thresholds in preterm infants be revised? *J Perinatology.* 2018;38(8):1022–1029.
23. Torella F, Haynes SL, McCollum CN. Cerebral and peripheral oxygen saturation during red cell transfusion. *J Surg Res.* 2003;110(1):217–21.
24. Stowell CP, Whitman G, Granger S, Gomez H, Assmann SF, Massey MJ, et al. The impact of red blood cell storage duration on tissue oxygenation in cardiac surgery. *J Thorac Cardiovasc Surg.* 2017;153(3):610–619.e2.
25. Podbregar M, Gavric AU, Podbregar E, Mozina H, Stefanovic S. Red blood cell transfusion and skeletal muscle tissue oxygenation in anaemic haematologic outpatients. *Radiol Oncol.* 2016;50(4):449–455.
26. McCredie VA, Piva S, Santos M, Xiong W, de Oliveira Manoel AL, Rigamonti A, et al. The impact of red blood cell transfusion on cerebral tissue oxygen saturation in severe traumatic brain injury. *Neurocritical Care.* 2017;26:247–255.
27. Carney N, Totten AM, Reilly CO, Ullman JS, Bell MJ, Bratton SL, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. *Neurosurgery.* 2016;80(1):1–10.
28. Tagliabue S, Kacprzak M, Serra I, Maruccia F, Fischer JB, Riveiro-Vilaboa M, et al. Transcranial, non-invasive evaluation of the potential misery perfusion during hyperventilation therapy of traumatic brain injury patients. *J Neurotrauma.* 2023;.
29. Tagliabue S, Lindner C, Chochron da Prat I, Sánchez-Guerrero A, Serra I, Kacprzak M, et al. Comparison of cerebral metabolic rate of oxygen, blood flow and bispectral index under general anesthesia. *Neurophotonics.* 2023;10(1):015006.
30. Lindner C, Mora M, Farzam P, Squarcia M, Johansson J, Weigel UM, et al. Diffuse Optical Characterization of the Healthy Human Thyroid Tissue and Two Pathological Case Studies. *PLOS ONE.* 2016 jan;11(1):e0147851.
31. Durduran T, Choe R, Baker WB, Yodh AG. Diffuse optics for tissue monitoring and tomography. *Rep Prog Phys.* 2010;73(7):076701.
32. Boas DA, Selb J, Franceschini MA, Carp SA, Selb J, Farzam P, et al. Establishing the diffuse correlation spectroscopy signal relationship with blood flow signal relationship with blood flow. *Neurophotonics.* 2016;3(3).
33. Torricelli A, Contini D, Pifferi A, Caffini M, Re R, Zucchelli L, et al. Time domain functional NIRS imaging for human brain mapping. *NeuroImage.* 2014;85:28–50.
34. Durduran T, Choe R, Baker WB, Yodh AG. Diffuse optics for tissue monitoring and tomography. *Rep Prog Phys.* 2010;73(7):076701.
35. Durduran T, Yodh AG. NeuroImage Diffuse correlation spectroscopy for non-invasive , micro-vascular cerebral blood flow measurement. *NeuroImage.* 2014;85:51–63.
36. Lee SY, Cowdrick KR, Sanders B, Sathialingam E, McCracken CE, Lam WA, et al. Noninvasive optical assessment of resting-state cerebral blood flow in children with sickle cell disease. *Neurophotonics.* 2019;6(3):1–7.
37. Sathialingam E, Williams EK, Lee SY, McCracken CE, Lam WA, Buckley EM. Hematocrit significantly confounds diffuse correlation spectroscopy measurements of blood flow. *Biomed Opt Express.* 2020;11(8):4786–4799.
38. Ko T, Mavroudis C, Baker W, Morano V, Mensah-Brown K, Boorady T, et al. Non-invasive optical neuromonitoring of the temperature-dependence of cerebral oxygen metabolism during deep hypothermic cardiopulmonary bypass in neonatal swine. *J Cereb Blood Flow Metab.* 2018 10;40:0271678X1880982.
39. Lee SY, Brothers RO, Turrentine KB, Quadri A, Sathialingam E, Cowdrick KR, et al. Quantifying the cerebral hemometabolic response to blood transfusion in pediatric sickle cell disease with diffuse optical spectroscopies. *Front Neurol.* 2022;1:13:869117.
40. Venkatasubramanian N, Prohovnik I, Hurler A, Mohr JP, Piomelli S. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. *Stroke.* 1994;25(11):2153–8.
41. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringner MN. Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage. *Stroke.* 2009;40(9):3039–44.
42. Juttukonda MR, Lee CA, Patel NJ, Davis LT, Waddle SL, Gindville MC, et al. Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia. *J Magn Reson Imaging.* 2018;49(2):466–477.
43. Guilliams KP RDECBMCLDAHMSJVKMRAHLJFA Fields ME. Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia. *Blood.* 2018;131(9):1012–1021.
44. Elizalde JI, Clemente J, Marin JL, Panés J, Aragón B, Mas A, et al. Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. *Transfus.* 1997;37.
45. van Hoften J, Verhagen E, Keating P, Horst H, Bos A. Cerebral tissue oxygen saturation and extraction in preterm infants before and after blood transfusion. *Arc Dis Child Fetal Neonatal Ed.* 2010 05;95:F352–8.
46. Torella F, Haynes SL, McCollum CN. Cerebral and peripheral oxygen saturation during red cell transfusion1 1A preliminary report. *J Surg Res.* 2003;110(1):217–221.
47. Creteur J, Neves AP, Vincent J. Near-infrared spectroscopy technique to evaluate the effects of red blood cell transfusion on tissue oxygenation. *Crit Care.* 2009;13 Suppl 5:S11.
48. Ito K, Ookawara S, Ueda Y, Uchida T, Kofuji M, Hayasaka H, et al. Blood transfusion during haemodialysis improves systemic tissue oxygenation: A case report. *Nefrologia.* 2017;37(4):435–437.
49. Neunhoeffer F, Hofbeck M, Schuhmann MU, Fuchs J, Schlensak C, Esslinger M, et al. Cerebral oxygen metabolism before and after RBC transfusion in infants following major surgical procedures. *Pediatric Critical*

- Care Medicine. 2018;19(4):318–327.
50. Strandgaard S, Paulson O. Cerebral autoregulation. *Stroke*. 1984;15.3:413–416.
 51. Paulson O, Strandgaard S, Edvinsson L. Cerebral autoregulation. *Cerebrovasc Brain Metab Rev*. 1990;2.2:161–192.
 52. Toth P, Szarka N, Farkas E, Ezer E, Czeiter E, Amrein K, et al. Traumatic brain injury-induced autoregulatory dysfunction and spreading depression-related neurovascular uncoupling: Pathomechanisms, perspectives, and therapeutic implications. *Am J Physiol Heart Circ Physiol*. 2016;311(5):H1118–H1131.
 53. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, et al. Clinical trials in head injury. *J Neurotrauma*. 2002 May;19(5):503–57.
 54. Durduran T, Yu G, Burnett MG, Detre JA, Greenberg JH, Wang J, et al. Diffuse optical measurement of blood flow, blood oxygenation, and metabolism in a human brain during sensorimotor cortex activation. *Opt Lett*. 2004 Aug;29(15):1766–1768.
 55. Strangman G, Franceschini MA, Boas DA. Factors affecting the accuracy of near-infrared spectroscopy concentration calculations for focal changes in oxygenation parameters. *NeuroImage*. 2003;18(4):865–879.
 56. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. *Bulletin of the World Health Organization*.
 57. Vos PE, vanVoskuilen AC, Beems T, Krabbe PF, Vogels OJ. Evaluation of the traumatic coma data bank computed tomography classification for severe head injury. *J Neurotrauma*. 2001;18(7):649–55.

Figures



Tables

ID	Sex	Polytrauma	TBI	GCS	Type of cerebral lesion*	Etiology	Hgb pre [g/dL]	Hgb post [g/dL]	HCT pre [%]	HCT post [%]	RBCs storage [days]
1	F	Yes	Yes	4	DI-IV	Traffic accident (motorcycle)	8.5	9.6	26	29	30
2	M	Yes	Yes	5	EML1	Traffic accident (car)	NA	NA	NA	NA	16
3	M	No	No	15	Not applicable	Suicide attempt (severe burns)	7.6	8.9	23	27	21
4	M	Yes	Yes	14	DI-I	Traffic accident (motorcycle)	8.2	8.9	25	27	16
5	M	Yes	Yes	7	DI-II	Traffic accident (motorcycle)	8	9.2	24	28	17
6	M	Yes	Yes	15	DI-I	Traffic accident (motorcycle)	8.2	8.9	25	27	26
7	M	No	No	15	Not applicable	Stroke	9.2	9.8	28	29	29
8	F	Yes	Yes	15	DI-I	Fall from height >3 meters	7.6	8.7	23	26	25
9	M	Yes	Yes	11	EML2	Fall from height >3 meters	8.9	10.5	27	32	21
10	M	Yes	Yes	14	DI-I	Traffic accident (motorcycle)	7.8	8.9	23	27	25
11	F	No	No	15	Not applicable	Stroke	7.9	9	24	27	21
12	M	No	No	15	Not applicable	Cerebral hematoma	7.8	8.8	23	26	21
13	M	Yes	Yes	6	DI-I	Hit by a train	7.9	8.7	24	26	20
14	M	Yes	No	15	Not applicable	Traffic accident (motorcycle)	7.6	8.4	23	25	17
15	M	No	No	15	Not applicable	Severe burns	8	9.1	24	27	12

Table 1: Demographic and clinical data (n=15). F: Female; GCS: Glasgow Coma Scale score, value at hospital admission; Hgb pre: blood hemoglobin concentration before transfusion (g/dL); Hgb post: blood hemoglobin concentration after transfusion (g/dL); M: Male; RBCs: Red blood cells; TBI: Traumatic brain injury; * Type of cerebral lesion according to the Traumatic Data bank Classification [57] in the computed tomography scan closest to the study. Diffuse injury I (DI-I): no visible intracranial pathology seen on CT scan; Diffuse injury II (DI-II): cisterns are present with midline shift 0-5 mm and/or high or mixed-density lesions ≤ 25cc; Diffuse injury III (DI-III): cisterns compressed or absent with midline shift 0-5 mm and/or high or mixed-density lesions ≤ 25cc; Diffuse injury IV (DI-IV): midline shift >5mm without high or mixed-density lesion > 25cc; Evacuated mass lesion (EML): any lesion surgically evacuated; Non evacuated mass lesion (NEML): high or mixed-density lesion > 25cc not surgically evacuated. 1: Epidural hematoma. 2: Subdural hematoma. Patient ID = 3 was discarded. NA: not available.

Variable	Pre-RBCT	Post-RBCT	Dir.	p-value
Hgb [g/dL]	8.1(0.48)	9.1(0.55)	↑	p<0.001
PaCO ₂ [mmHg]	39.4(4.3)	40(4.5)	-	p=0.22
HCT [%]	24.5(1.6)	27.4(1.8)	↑	p<0.001

Table 2: Results in terms of mean(SD) for Hgb, PaCO₂ and HCT values obtained by blood gas analysis pre- and post-transfusion (pre-RBCT and post-RBCT). Post-transfusion values were tested against pre-transfusion values to verify whether had undergone a statistically significant change (significant when the p-value (p) <0.05). Additionally, an arrow upwards indicates that the post- values increased (median value for the distribution higher than for the pre-transfusion values), while a downwards arrow stays for a decrease. Hgb: Arterial total hemoglobin concentration, measured by blood gas analysis; PaCO₂: Arterial pressure of carbon dioxide; HCT: Hematocrit; RBCT: red blood cell transfusion. Dir.: direction of change.

Variable	Cerebral		Peripheral		Cerebral VS peripheral	
	p-value	Dir.	p-value	Dir.	p-value	Dir.
rBF	0.07	-	<0.001	↑	0.1	-
rOEF	<0.001	↓	<0.001	↓	0.2	-
rMRO ₂	0.03	↑	<0.001	↑	0.03	↑ *
Δ[HbO ₂]	0.008	↑	<0.001	↑	0.9	-
Δ[Hhb]	0.2	-	0.1	-	0.2	-
Δ[HbT]	0.01	↑	<0.001	↑	0.5	-

Table 3: Summary of the results of all tests carried out for the optically derived variables (rBF, rOEF, rMRO₂, Δ[HbO₂], Δ[Hhb], Δ[HbT]). Under the column ‘Cerebral’, the post-transfusion values were tested for difference with respect to baseline. The results concerning the post-transfusion muscle-related values are reported below ‘Peripheral’, again tested with respect to baseline. Post-transfusion values for the cerebral level were tested for significant difference with respect to the post-transfusion values at peripheral level in the last column (‘Cerebral versus peripheral’). Significance was defined as p-values lower than 0.05. The direction (Dir.) of the change of the median value for the distribution is represented by an arrow: upwards if it increased, downwards if decreased. * in this case the arrow indicates that the peripheral level was significantly higher than the cerebral level after RBCT. rBF: relative blood flow; rOEF: relative oxygen extraction fraction; rMRO₂: relative metabolic rate of oxygen; Δ[HbT]: Change in [HbT]; Δ[HbO₂]: Change in [HbO₂]; Δ[Hhb]: Change in [Hhb].




Figure 2: Time-traces collected during the RBCT of a patient for an entire protocol, comprising baseline pre-RBCT, blood unit transfusion and post-transfusion period. Non-invasive signals are depicted with peripheral and cerebral recordings color-coded as shown in the legend. The beginning and end of the process are highlighted by thick dashed vertical lines, synchronized in time for all variables. Additional events marked during the protocol are represented by vertical lines.




Figure 3: Graphs representing the post-transfusion data distribution for all optically-derived variables and divided into cerebral and peripheral muscle. For each distribution of mean values, its boxplot is represented (median, first and third quartiles). Dashed grey lines are drawn indicating the baseline pre-RBCT values for the distributions, which they are relative to and compared with. Subjects are color coded in the same way for all variables. An asterisk on the top of a boxplot indicates that the distribution tested significantly different than the baseline. No significant difference was found between peripheral and cerebral post-transfusion values apart from the metabolic rate of oxygen.

Acronym	Parameter	Method
Hgb	arterial total hemoglobin concentration	blood gas analysis
HgbO ₂	arterial oxy-hemoglobin concentration	blood gas analysis
Hgbr	arterial reduced hemoglobin concentration	blood gas analysis
[HbT]	microvascular total hemoglobin concentration	diffuse topics
[HbO ₂]	microvascular oxy-hemoglobin concentration	diffuse topics
[Hhb]	microvascular deoxy-hemoglobin concentration	diffuse topics

Table 4: Acronyms of the parameters related to hemoglobin concentration, to clarify which one is derived by which method.